Immunicum AB: Immunicum AB (publ) Interim Report January – March 2022
JANUARY - MARCH IN SUMMARY
- Net sales for the period amounted to KSEK 1,794 (–).
- Result for the period amounted to KSEK -27,582 (-41,571).
- Earnings and diluted earnings per share totaled SEK -0.14 (-0.25).
- Immunicum transfers patent rights for modified adenovirus to Elicera Therapeutics
- Immunicum provided a pipeline and strategy outlook. In 2022, the clinical development focus will be on i) the continuation and further clinical data updates of the ADVANCE II study evaluating DCP-001 in the acute myeloid leukemia (AML) maintenance setting,
ii) the continuation of the ALISON study in ovarian cancer, which will deliver a first clinical read-out in 2022 and iii) the evaluation and preparation of the TROY study, which will evaluate Ilixadencel’s potential in gastrointestinal stromal tumors (GIST)
- Immunicum has made further progress in establishing its new core research facility in Leiden, The Netherlands, which will incorporate the company’s process development and manufacturing capabilities for cell-based immune therapies. The company expects to finalize the move into its new facilities in Q2 2022.
- Continued progress in exploring potential synergies of Immunicum’s platform and product candidates with current standard-of-care in Immunicum’s key cancer indications, and other cell-based cancer therapies and biologics in development in oncology
COVID-19, UKRAINE CRISIS
- To date, Immunicum has experienced only limited impact to its operations owing to the Covid-19 pandemic
- Immunicum has no direct exposure to the Ukraine and Russia related to its daily operations and ongoing clinical trials
- Continued stock market and supply chain uncertainties may affect our operations longer-term
- For further information, please go to the risk section on page 18.
SIGNIFICANT EVENTS AFTER END OF PERIOD
- Immunicum to participate in the new cancer research consortium Oncode-PACT
- Immunicum to present preclinical data demonstrating synergy of DCP-001 with standard treatments for Acute Myeloid Leukemia
- Immunicum appoints Leopold Bertea as Chief Technology Officer
|KSEK unless otherwise stated||2022||2021||2021|
|Earnings/loss per share, before and after dilution (SEK)||-0.14||-0.25||-0.73|
|Number of employees at the end of the period||32||30||29|
“In the first quarter of 2022, Immunicum presented its revised pipeline and strategy outlook, via investor events held in Stockholm and Gothenburg, Sweden.
In 2022, we will gain more visibility on how the promising initial effects of our cancer relapse vaccine DCP-001 presented at the ASH2021 conference last December will translate into potential relapse-free and overall survival benefit for acute myeloid leukemia patients with measurable residual disease (MRD). We expect to provide a next update of the ADVANCE II study based on complete MRD data of all treated patients and relapse-free survival status in Q2 2022.
In the ALISON Phase I study initiated in 2021, we are studying safety and feasibility of DCP-001 in ovarian cancer. If successful, the trial could open up the development of relapse vaccination as new maintenance therapy in ovarian cancer. Initial data from the ALISON study are expected mid-2022.
Out of the different indications studied so far with our intratumoral immune primer ilixadencel, we believe that gastrointestinal stromal tumors (GIST) represent the most attractive opportunity, due to the very low response rates to currently available therapies following initial treatment failure. The recently published results of the MERECA study in renal cell carcinoma have further increased our understanding of the biology and therapeutic combination potential of ilixadencel with tyrosine kinase inhibitors such as sunitinib. This provides further basis for our ongoing preparations of a clinical trial in combination with tyrosine kinase inhibitors in GIST.
In Q1 2022, we initiated the move to our new R&D facilities in the Leiden, The Netherlands. Our in-house R&D expertise supports the clinical pipeline, the optimization of our manufacturing processes and partnering efforts. Immunicum participates in the new cancer research consortium Oncode-PACT, which is funded by the Dutch National Growth Fund and will be supportive in the expansion of our Leiden-based R&D facilities.
Despite the challenging conditions for the biopharmaceutical industry related to the Covid crisis, geopolitical instability and related disruption of hospitals and supply chain, the merger and integration of Immunicum and DCprime, subsequent directional pipeline decisions and promising novel R&D initiatives have allowed the Company to make significant progress in 2021 and to define our most promising programs in the first quarter of 2022. We remain committed to addressing key challenges in the cancer therapy landscape with competitive product candidates and look forward to the further shaping of our clinical pipeline in 2022.
Finally, while his appointment happened after the close of the reporting period, I would like to use the opportunity to welcome Leopold Bertea, PhD, as our new Chief Technology Officer. Leopold brings an impressive track record in cell therapy process development and production, including commercial-scale manufacturing to Immunicum. He will be driving the build-up of a global manufacturing infrastructure for DCP-001 and building out of the company’s process development capabilities for our current and future products.
Erik Manting, Ph.D.
Chief Executive Officer”
The Q1 2022 report is available on: http://immunicum.se/investors/financial-reports/
FOR MORE INFORMATION, PLEASE CONTACT:
Chief Executive Officer
Stern Investor Relations
Telephone: +1 212-362-1200
Telephone: +49 160 9352 9951
ABOUT IMMUNICUM AB (PUBL)
Immunicum is a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, two key challenges in oncology. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based therapies for blood-borne and solid tumors. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
FRO – Private acquisitions of Euronav shares in exchange for Frontline shares completed28.5.2022 12:01:09 CEST | Press release
FRO – Private acquisitions of Euronav shares in exchange for Frontline shares completed Frontline Ltd. (“Frontline” or the "Company") (NYSE: FRO – OSE: FRO) announces that it has agreed to acquire a total of 5,955,705 shares in Euronav N.V. (NYSE: EURN & Euronext: EURN) (“Euronav”) representing 2.95% of the outstanding shares in privately negotiated share exchange transactions with certain shareholders of Euronav N.V. where such shareholders of Euronav N.V. receive consideration shares in Frontline. Frontline will issue a total of 8,337,986 new shares as a result of these transactions, equivalent to an exchange ratio of 1.4. Frontline will be entitled to the declared USD 0,06 dividend to be paid by Euronav on the acquired shares on 8 June 2022. Settlement is expected to take place on or about 1 June 2022 by delivery of existing shares through a share lending arrangement with Frontline's main shareholder Hemen Holding Ltd. Following completion of the issue of the new Frontline shares, F
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma28.5.2022 00:58:29 CEST | Press release
68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from Kymriah treatment demonstrated – of patients who achieved a complete response, 85% were still in response at 12 months1 Kymriah can be administered in the outpatient setting, offering increased flexibility and potentially reducing the burden of therapy for patients and their care teams1,2 Kymriah is now FDA approved in three indications and remains the only CAR-T cell therapy approved in both adult and pediatric settings1 Basel, May 28, 2022 — Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah® (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. In accordance with the Accelerated Approval Program, continued approval for this indicati
ObsEva Announces Corporate Updates27.5.2022 22:01:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland– May 27, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, announced today that it has entered into a waiver and amendment agreement (Amendment Agreement) with respect to its amended and restated securities purchase agreement (Securities Purchase Agreement) with certain funds and accounts managed by JGB Management, Inc. (JGB), which is structured to provide up to $135 million in borrowing capacity, available in nine tranches. The third tranche under the Securities Purchase Agreement was due to be funded on May 25, 2022. However, the tranche has not been funded as a result of ObsEva not meeting the funding condition that its volume-weighted average share price would not trade below $3.00 per share for five or more trading days during the 30 days prior to the funding date for the third tranche. Pursuant to the Am
CONDITIONS FOR PURCHASES OF CORPORATE BONDS27.5.2022 16:20:00 CEST | Press release
Bid procedure, 2022-06-01BondsBonds issued in SEK by Swedish non-financial undertakings. The following bonds are eligible for delivery: HEMSO FASTIGHETS AB: XS2173253407, 2025-05-13 HEMSO FASTIGHETS AB: XS2269194572, 2023-12-07 VASAKRONAN AB: SE0010599183, 2023-12-20 VASAKRONAN AB: XS2391917205, 2025-03-28 ESSITY AB: XS2355204608, 2025-01-17 SCANIA CV AB: XS2297918349, 2023-11-11 SCANIA CV AB: XS2382157571, 2024-09-02 ELECTROLUX AB: XS2152294679, 2023-04-06 ELECTROLUX AB: XS1969611943, 2024-03-27 Delivery of a Bond may not occur if the Counterparty has purchased the Bond from the issuer more recently than one month prior to the date of announcement of the Special terms, that is, the purchase may not have taken place after: 2022-04-27Bid date2022-06-01Bid times10.30-11.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)XS2173253407: 30 mln SEK +/-30 mln SEK XS2269194572: 30 mln SEK +/-30 mln SEK SE0010599183: 30 mln SEK +/-30 mln SEK XS2391917205: 30 mln SEK +/-
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS27.5.2022 16:20:00 CEST | Press release
Bid procedure, 2022-06-03BondsSWEDEN I/L BOND: 3113. SE0009548704. 2027-12-01 SWEDEN I/L BOND: 3114, SE0013748258, 2030-06-01 Bid date2022-06-03Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)3113: 250 mln SEK +/-125 mln SEK 3114: 250 mln SEK +/-125 mln SEK Highest permitted bid volume (corresponding nominal amount)3113: 250 mln SEK per bid 3114: 250 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2022-06-08Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2022-05-27 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be